DEMECAN signs binding supply agreement with Australia-based medical cannabis producer
DEMECAN announces the signing of a three-year supply agreement with Australian-based medical cannabis producer, Little Green Pharma, marking yet another milestone in DEMECAN’s path to guarantee a consistent supply of pharmaceutical grade cannabis to patients in Germany. The agreement is for an annual amount of at least 1,000 kg of dried flower or 48,000 units of medical cannabis oil.
“We are delighted to work together with Little Green Pharma to ensure the supply of high-quality medical cannabis products for German patients,” says Dr. Cornelius Maurer, managing director at DEMECAN.
The first shipments of medical cannabis from Australia are expected in the second half of 2020 and will complement the supply from the Netherlands, Canada, and other countries as well as DEMECAN’s own domestic production.
Berlin, February 27, 2020
DEMECAN is the only German company that covers the entire value chain for medical cannabis from cultivation, processing, and storage to distribution to pharmacies. In May 2019, the Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN the contract to grow medical cannabis. DEMECAN is based in Berlin.The cultivation and processing of medical cannabis takes place in a second facility near Dresden.
Exchange and dialogue:
We are always open for questions about DEMECAN, medical cannabis, and opportunities around phytopharmacological research. Any questions related to regulatory affairs and all questions by regulatory authorities should be directed to firstname.lastname@example.org.